Cefteram
Chemical compound
- J01DD18 (WHO)
- In general: ℞ (Prescription only)
- (6R,7R)-7-([(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino)-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 82547-58-8
- 6537431
- 4576594
- 74CQ4Q3N63
- D07655
- ChEMBL2105953
- DTXSID7048821
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)Cn4nc(nn4)C)C(=O)O
Cefteram (INN) is a third-generation cephalosporin antibiotic.[1]
References
- ^ Yamaguchi K, Ohno A, Takahashi S, Hayashi M, Yamanaka K, Hirakata Y, Mitsuyama J (January 1998). "[In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates]". The Japanese Journal of Antibiotics. 51 (1): 11–25. PMID 9557273.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e